Related Experiment Videos
The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines
1Virginia Commonwealth University School of Pharmacy, Richmond, USA. mckenney@gems.vcu.edu
Insights
Aggressive lipid management for coronary heart disease (CHD) is recommended by National Cholesterol Education Program (NCEP) guidelines. Atorvastatin demonstrated superior cost-effectiveness in achieving NCEP lipid goals compared to other statins.
Area of Science:
- Cardiovascular Medicine
- Pharmacoeconomics
- Public Health
Background:
- Coronary heart disease (CHD) is a leading cause of mortality in industrialized nations, imposing significant healthcare and productivity burdens.
- National Cholesterol Education Program (NCEP) guidelines advocate for intensive lipid-modifying therapy in high-risk individuals.
- A substantial portion of the US population (over 50 million) may benefit from interventions to improve lipid profiles, yet many on therapy do not meet NCEP targets.
Purpose of the Study:
- To evaluate the pharmacoeconomic implications of National Cholesterol Education Program (NCEP) guidelines for lipid management.
- To compare the cost-effectiveness of different statin therapies in achieving NCEP lipid goals.
- To assess the economic impact of primary versus secondary prevention strategies for hypercholesterolemia.
Main Methods:
- Review of existing pharmacoeconomic analyses of NCEP guidelines.
- A 54-week randomized prospective study comparing atorvastatin with fluvastatin, lovastatin, and simvastatin in 662 hypercholesterolemic patients.
- Concurrent measurement of medical outcomes and economic data, including cost to achieve NCEP goals.
Main Results:
- Pharmacoeconomic data suggest secondary prevention is more cost-effective than primary prevention, with primary prevention costs aligning with accepted medical interventions.
- Atorvastatin treatment led to a significantly higher likelihood and faster achievement of NCEP goals compared to other statins studied.
- The mean cost to reach NCEP goals was lowest for patients treated with atorvastatin.
Conclusions:
- Pharmacoeconomic findings support the NCEP treatment guidelines for hypercholesterolemia.
- Atorvastatin presents a cost-effective option for achieving lipid management goals in patients with hypercholesterolemia.
- Optimizing lipid-lowering therapy according to NCEP guidelines can improve both clinical outcomes and economic efficiency.
Abstract:
Coronary heart disease (CHD) is a major cause of death in industrialised countries and places a large burden on society in terms of healthcare resources and lost productivity. US National Cholesterol Education Program (NCEP) guidelines recommend aggressive lipid-modifying therapy for individuals at highest risk for CHD. It has been estimated that more than 50 million individuals in the US (more than one-third of the total population) are candidates for some form of dietary and/or pharmacological intervention to modify their lipid profiles. Most individuals who receive lipid-lowering drug therapy do not meet target goals set by the NCEP; thus, there is a large potential for increased use of drug therapy. Pharmacoeconomic analyses applying NCEP guidelines are sparse; however, available data (using direct costs) suggest that secondary prevention is more cost effective than primary prevention, but that costs associated with primary prevention are generally in line with those of accepted medical interventions. Cost-effectiveness ratios for secondary prevention improved when indirect costs were assessed in one study. A recent randomised prospective 54-week comparative study of statins in 662 patients with hypercholesterolaemia concurrently measured medical outcomes and economic data. Atorvastatin-treated patients were significantly more likely to achieve NCEP goals (overall and at the initial dosage), and to achieve these goals more quickly than patients treated with fluvastatin, lovastatin and simvastatin. The mean cost to reach NCEP goals was consequently lowest for atorvastatin. Results from pharmacoeconomic studies of primary and secondary prevention are therefore in support of NCEP treatment guidelines for hypercholesterolaemia.